Moderna says uncertain about coronavirus vaccine patent exclusivity
Reuters
Published Aug 11, 2020 12:26PM ET
(Reuters) - Moderna Inc (O:MRNA) said there was a possibility it was not the first company to make breakthroughs claimed in its patent applications, including those for its experimental coronavirus vaccine, according to a recent regulatory filing.
The statement by the U.S. drug developer was made in a quarterly filing on Aug. 6 under mandatory disclosures of risks to its business.
Moderna's prior quarterly filings with U.S. regulators did not have the disclosure.
"For this and other reasons, we may be unable to secure desired patent rights, thereby losing exclusivity," the company said. (https://
The company has received funding from the U.S. government to develop its coronavirus vaccine, and in July lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma Corp (O:ABUS) that poses a potential obstacle to Moderna's efforts to develop next-generation vaccines.
"We cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions, including mRNA-1273," the company said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.